Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam S Cheifetz

Showing results (11-20 of 202) with videos related to

Pageof 21
Sort By:
Inflammatory Bowel Diseases|November 6, 2010
Infliximab decreases colectomy rates in moderate to severe ulcerative colitis: big news or big deal?Adam S Cheifetz, Laura Rosenberg
The American Journal of Gastroenterology|February 22, 2017
Therapeutic Drug Monitoring in IBD: The New Standard-of-Care for Anti-TNF TherapyKonstantinos Papamichael, Adam S Cheifetz
Current Opinion in Gastroenterology|April 12, 2019
Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?Konstantinos Papamichael, Adam S Cheifetz
Alimentary Pharmacology & Therapeutics|November 19, 2024
Editorial: Is There a Role for Therapeutic Drug Monitoring of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease?Konstantinos Papamichael, Adam S Cheifetz
World Journal of Gastroenterology|October 5, 2017
Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapyKonstantinos Papamichael, Adam S Cheifetz
Journal of Crohn'S & Colitis|November 26, 2019
Proactive Adalimumab Monitoring in Inflammatory Bowel Disease: Current Data and Future PerspectivesKonstantinos Papamichael, Adam S Cheifetz
Frontline Gastroenterology|August 26, 2017
Use of anti-TNF drug levels to optimise patient managementKonstantinos Papamichael, Adam S Cheifetz
The American Journal of Gastroenterology|December 8, 2017
Response to ReininkKonstantinos Papamichael, Adam S Cheifetz
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 28, 2020
Therapeutic Drug Monitoring and Safety of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel DiseaseKonstantinos Papamichael, Adam S Cheifetz
Mayo Clinic Proceedings|June 12, 2017
Crohn Disease: Epidemiology, Diagnosis, and ManagementJoseph D Feuerstein, Adam S Cheifetz
Pageof 21

Showing results (11-20 of 202) with videos related to

Sort By:
Pageof 21
Inflammatory Bowel Diseases|November 6, 2010
Infliximab decreases colectomy rates in moderate to severe ulcerative colitis: big news or big deal?Adam S Cheifetz, Laura Rosenberg
The American Journal of Gastroenterology|February 22, 2017
Therapeutic Drug Monitoring in IBD: The New Standard-of-Care for Anti-TNF TherapyKonstantinos Papamichael, Adam S Cheifetz
Current Opinion in Gastroenterology|April 12, 2019
Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?Konstantinos Papamichael, Adam S Cheifetz
Alimentary Pharmacology & Therapeutics|November 19, 2024
Editorial: Is There a Role for Therapeutic Drug Monitoring of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease?Konstantinos Papamichael, Adam S Cheifetz
World Journal of Gastroenterology|October 5, 2017
Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapyKonstantinos Papamichael, Adam S Cheifetz
Journal of Crohn'S & Colitis|November 26, 2019
Proactive Adalimumab Monitoring in Inflammatory Bowel Disease: Current Data and Future PerspectivesKonstantinos Papamichael, Adam S Cheifetz
Frontline Gastroenterology|August 26, 2017
Use of anti-TNF drug levels to optimise patient managementKonstantinos Papamichael, Adam S Cheifetz
The American Journal of Gastroenterology|December 8, 2017
Response to ReininkKonstantinos Papamichael, Adam S Cheifetz
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 28, 2020
Therapeutic Drug Monitoring and Safety of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel DiseaseKonstantinos Papamichael, Adam S Cheifetz
Mayo Clinic Proceedings|June 12, 2017
Crohn Disease: Epidemiology, Diagnosis, and ManagementJoseph D Feuerstein, Adam S Cheifetz
Pageof 21